Relistor methylnaltrexone regulatory update

FDA approved an sNDA from Salix for subcutaneous Relistor methylnaltrexone to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. The peripheral mu opioid receptor ( OPRM1; MOR) antagonist is approved in the U.S. to treat OIC in patients with advanced illness who are receiving palliative care when response to laxative therapy has not been sufficient (see BioCentury, July 21 & Aug. 18). ...